Interstitial lung diseases: from disease mechanisms to novel treatment options

Journal session
Chairs: S. Meiners (Sülfeld, Germany), K. Antoniou (Heraklion, Greece)
Aims: To provide new insights into disease pathogenesis; to highlight the clinical promise of disease biomarkers; to consider current diagnostic approaches; to describe the range of treatment options available or being developed for patients with interstitial lung disease; to set out future directions for research and clinical practice.

Introduction R. Craven (London, United Kingdom)
Disease pathology in interstitial lung disease E. Renzoni (London, United Kingdom)
Biomarker discovery, development, and implementation in interstitial lung diseases G. Jenkins (London, United Kingdom)
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities P. Spagnolo (Padova (PD), Italy)
Treatment of interstitial lung diseases: current approaches and future directions K. Johannson (Calgary (AB), Canada)
Discussion and Q&A
Conclusions R. Craven (London, United Kingdom)